NewsRelease
ResearchArticle Cites Cleanascite™ for Analyzing Membrane InteractionProteins
MONMOUTHJUNCTION, NJ,April4, 2017 -- Biotech Support Group reports on a recent research articledescribing the simplicity and efficiency of their lipid clearancetechnology for cell culture lysates.
Thecitation is:
Ahmed,Syed Mukhtar, and Ian G. Macara. "The Par3 polarity protein isan exocyst receptor essential for mammary cell survival." NatureCommunications8 (2017): 14867. doi:10.1038/ncomms14867
Inbrief, the article’s authors aimed to identify a receptor ofthe exocyst, an essential component of the secretory pathway requiredfor delivery of basolateral proteins to the plasma membranes ofepithelial cells. To determine if phospholipids were essential forthe interaction, a lipid-binding resin was used to remove lipids. Thearticle states “Lipids from cells and bacterial lysates wereremoved using Cleanascite™…â€�. The authors concludethat Par3 is an exocyst receptor required for targeted membrane-protein delivery.
“Thisreference shows that Cleanascite™efficiently removes lipids so essential interactions of membraneproteins can be evaluatedâ€� states Swapan Roy, Ph.D., Presidentand Founder of Biotech Support Group.
Formore information visit: Cleanascite™Lipid Removal Reagent and Clarification,at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ forlipid adsorption, HemogloBind™ and HemoVoid™ forhemoglobin removal, and NuGel™ for functional proteomics. Fromthese innovations, the company has acquired knowledgebase andbiomarker intellectual property assets that support discoveries ofprotein markers from blood, with special emphasis on early detectionand personalized medical decisions for cancer patients. For moreinformation, go tohttp://www.biotechsupportgroup.com
Contact:
MatthewKuruc 732-274-2866